Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011–2018

BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) entered Cameroon’s childhood national immunization programme (NIP) in July 2011 under a 3-dose schedule (6, 10, 14 weeks of age) without any catch-up. We described the impact of PCV13 onserotype distribution among pneumococcal meningit...

Descripción completa

Detalles Bibliográficos
Autores principales: Njuma Libwea, John, A. Fletcher, Mark, Koki Ndombo, Paul, Boula, Angeline, Ashukem, Nadesh Taku, Ngo Baleba, Madeleine, Kingue Bebey, Rachel Sandrine, Nkolo Mviena, Eric Gaston, Tageube, Jean, Kobela Mbollo, Marie, Koulla-Shiro, Sinata, Madhi, Shabir, Njanpop-Lafourcade, Berthe-Marie, Mohammad, Ali, Begier, Elizabeth, Southern, Joanna, Beavon, Rohini, Gessner, Bradford
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049353/
https://www.ncbi.nlm.nih.gov/pubmed/33857235
http://dx.doi.org/10.1371/journal.pone.0250010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049353/
https://www.ncbi.nlm.nih.gov/pubmed/33857235
http://dx.doi.org/10.1371/journal.pone.0250010

Ejemplares similares